We found that the FDA-approved drug ibrutinib, which has been used for treating relapsed/refractory nongerminal center B-cell-like diffuse large B-cell lymphoma (DLBCL) in clinical trials50, was recently reported to be an MKK7 inhibitor38, and we found that it effectively suppresses OSCS and tumorigenesis in OTUD1high ovarian cancer and sensitizes cancer cells to chemotherapy. This evidence concerns the gene MAP2K7 and ovarian carcinoma.